Exploring Polθ as a New DDR Target
Time: 4:30 pm
day: Day One
Details:
- Discovery and preclinical development of first-in-class inhibitors for oncology in a PARP-resistant setting
- Leveraging synthetic lethality and understanding of the theta-mediated end joining (TMEJ) to determine a validated target
- Latest from the lab, clinical validation, and future directions
- Discussing how it will compare to PARP
- Dissecting how to leverage it as a novel target
- Combination – who, where, what?
